Rehaneo Welcomes Fremman Capital as New Majority Stakeholder
Deal News | Nov 20, 2024 | GIMV NV (ENXTBR:GIMB)
Belgian investment firm Gimv NV has sold its majority stake in Rehaneo to Fremman Capital, marking a pivotal moment in the outpatient rehabilitation sector. Rehaneo, established in 2020 during the peak of the COVID-19 pandemic, has evolved into one of Germany's top three outpatient rehabilitation providers through a strategic buy-and-build approach. Under the continued leadership of Founder and CEO Bruno Crone and COO Christoph Dhr, the company has expanded rapidly, integrating 13 facilities across 23 locations and employing over 1,000 personnel who serve more than 80,000 patients annually. This strategic transaction aims to bolster Rehaneo's growth strategy, focusing on networking outpatient care and consolidating the fragmented market. The deal, subject to German antitrust approval, is expected to close by Q1 2025 and promises significant financial returns for Gimv, impacting its NAV positively by about EUR 1 per share.
Sectors
- Healthcare
- Private Equity
- Mergers & Acquisitions
Geography
- Germany – Rehaneo is based in Germany, with operations across 23 locations in the country.
- Belgium – Gimv NV, the selling party, is a Belgian investment firm.
Industry
- Healthcare – The article is centered around Rehaneo, a provider of outpatient rehabilitation services, indicating a primary focus on healthcare.
- Private Equity – The transaction involves private equity firms Gimv and Fremman Capital, highlighting activities within the private equity sector.
- Mergers & Acquisitions – Rehaneo's buy-and-build strategy and future M&A plans indicate significant activity in mergers and acquisitions.
Financials
- EUR 1 per share – The transaction's impact on Gimv's NAV as of 30 September 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Rehaneo | Target Company | Company | A leading provider of outpatient rehabilitation and related services in Germany. |
| Gimv NV | Selling Company | Company | A European investment company divesting its majority stake in Rehaneo. |
| Fremman Capital | Bidding Company | Company | An investment firm acquiring the majority stake in Rehaneo. |
| German Antitrust Authorities | Regulatory Body | Government | Responsible for approving the transaction between Gimv and Fremman Capital. |
| Bruno Crone | CEO | Person | Founder and CEO of Rehaneo, continuing to lead the company post-transaction. |
| Christoph Dhr | COO | Person | Co-founder and COO of Rehaneo, retaining a leadership role. |
| Dr. Alain Robbe-Grillet | CFO | Person | Joined the Rehaneo management team as CFO in 2023. |
| Prof. Dr. med. Thomas Wessinghage | Medical Board Expert | Person | Part of the medical board ensuring quality services at Rehaneo. |